Literature DB >> 2424048

The interferon system in acute and chronic viral hepatitis.

M Peters, G L Davis, J S Dooley, J H Hoofnagle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2424048

Source DB:  PubMed          Journal:  Prog Liver Dis        ISSN： 1060-913X


× No keyword cloud information.
  15 in total

1.  Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C.

Authors:  D F Stein; A Ahmed; V Sunkhara; W Khalbuss
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

2.  The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals.

Authors:  Y K Yoo; J B Gavaler; K Chen; T L Whiteside; D H van Thiel
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 3.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

4.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.

Authors:  H J Flink; D Sprengers; B E Hansen; M van Zonneveld; R A de Man; S W Schalm; H L A Janssen
Journal:  Gut       Date:  2005-05-29       Impact factor: 23.059

Review 5.  Interferon in the management of chronic hepatitis B.

Authors:  R P Perrillo
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

6.  The serology of chronic hepatitis B infection revisited.

Authors:  T Maruyama; A McLachlan; S Iino; K Koike; K Kurokawa; D R Milich
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

7.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

Review 8.  Treatment of chronic hepatitis C: impact of combination therapy.

Authors:  G L Davis
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 9.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.

Authors:  T Okuno; M Shindo; K Arai; M Matsumoto; M Takeda; K Kashima; Y Sokawa
Journal:  Gastroenterol Jpn       Date:  1991-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.